Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 14/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5026710 | 0.82 | F10 (1.00) | F10L3MBTL1POLBALDH1A1LMNA | |
| SCHEMBL5022242 | 0.81 | F10 (0.77) | F10L3MBTL1POLBALDH1A1LMNA | |
| SCHEMBL4445875 | 0.81 | F10 (1.00) | F10 | |
| SCHEMBL5022491 | 0.80 | F10 (0.76) | F10L3MBTL1POLBALDH1A1LMNA | |
| SCHEMBL5023474 | 0.80 | F10 (0.76) | F10L3MBTL1POLBALDH1A1LMNA | |
| SCHEMBL5022987 | 0.80 | F10 (0.76) | F10L3MBTL1POLBHTTALDH1A1 | |
| SCHEMBL4443718 | 0.79 | F10 (0.94) | F10L3MBTL1POLBMEN1KMT2A | |
| SCHEMBL5023535 | 0.78 | F10 (0.73) | F10L3MBTL1POLBALDH1A1LMNA | |
| SCHEMBL5023423 | 0.78 | F10 (0.73) | F10L3MBTL1POLBALDH1A1LMNA | |
| SCHEMBL4443639 | 0.78 | F10 (1.00) | F10L3MBTL1POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550487-B2 | Pyrrolidine-3,4-dicarboxamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-06-23 | — | — | US | disclosed |
| EP-1732918-B1 | NOVEL PYRROLIDINE-3,4-DICARBOXAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-11-12 | — | — | EP | disclosed |
| EP-1732918-A1 | NOVEL PYRROLIDINE-3,4-DICARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005092881-A1 | NOVEL PYRROLIDINE-3,4-DICARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-10-06 | — | — | WO | disclosed |
| US-20050215599-A1 | Pyrrolidine-3,4-dicarboxamide derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215599-A1 | Pyrrolidine-3,4-dicarboxamide derivatives | F9, F2, F12 | F10 7/4885L3MBTL1 4664/4885POLB 2555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.